116 related articles for article (PubMed ID: 3601584)
1. Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukaemia.
Miszlai Z; Czink E; Varga L; Pálóczi K; Szegedi G; Füst G; Hollán SR
Acta Med Hung; 1986; 43(4):389-95. PubMed ID: 3601584
[TBL] [Abstract][Full Text] [Related]
2. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
[TBL] [Abstract][Full Text] [Related]
3. C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance.
Füst G; Miszlay Z; Czink E; Varga L; Pálóczi K; Szegedi G; Hollán SR
Immunol Lett; 1987 Feb; 14(3):255-9. PubMed ID: 3570363
[TBL] [Abstract][Full Text] [Related]
4. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
5. Acquired C1-esterase inhibitor deficiency and recurrent herpes infection in a patient with chronic lymphocytic leukemia.
Minh D; Czink E; Füst G; Hollán SR
Diagn Immunol; 1983; 1(2):68-71. PubMed ID: 6680094
[TBL] [Abstract][Full Text] [Related]
6. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naïve patients.
Varga L; Széplaki G; Visy B; Füst G; Harmat G; Miklós K; Németh J; Cervenak L; Karádi I; Farkas H
Mol Immunol; 2007 Feb; 44(6):1454-60. PubMed ID: 16750855
[TBL] [Abstract][Full Text] [Related]
7. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
8. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.
Füst G; Medgyesi GA; Rajnavölgyi E; Csécsi-Nagy M; Czikora K; Gergely J
Immunology; 1978 Dec; 35(6):873-84. PubMed ID: 104923
[TBL] [Abstract][Full Text] [Related]
9. Complement and IgG subclasses in agammaglobulinemic patients.
Grumach AS; Kirschfink M
Exp Clin Immunogenet; 1995; 12(1):10-5. PubMed ID: 7710760
[TBL] [Abstract][Full Text] [Related]
10. In vitro effects of organic solvents on immunity indicators in serum.
Stefanovic J; Starsia Z; Murgasová I; Absolonová O
J Hyg Epidemiol Microbiol Immunol; 1987; 31(1):1-7. PubMed ID: 3571967
[TBL] [Abstract][Full Text] [Related]
11. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
Giclas PC
J Immunol; 1982 Jul; 129(1):168-72. PubMed ID: 6979566
[TBL] [Abstract][Full Text] [Related]
12. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
Doekes G; van Es LA; Daha MR
Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
[TBL] [Abstract][Full Text] [Related]
13. [Complement and serum immunoglobulins in homozygous and heterozygous sickle cell anemia in Senegal].
Dieye TN; Ndiaye O; Ndiaye AB; Thiam D; Fall-Seck K; Diop S; Diop BM; Fall M; Diakhaté L
Dakar Med; 1999; 44(2):175-9. PubMed ID: 11957280
[TBL] [Abstract][Full Text] [Related]
14. [Consumption hypocomplementemia: comparative value of haemolytic and protein estimations of the components of the classical pathway (author's transl)].
Roncato M; Vial MC; Maillet F; Peltier A
Nouv Presse Med; 1979 May; 8(20):1657-60. PubMed ID: 112575
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of immunoglobulins and complement components in patients with recurrence after resection of gastric carcinoma.
Janssen CW; Tønder O; Matre R
Cancer Detect Prev; 1987; 10(3-4):303-9. PubMed ID: 3568028
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
Beebe DP; Schreiber RD; Cooper NR
J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
[TBL] [Abstract][Full Text] [Related]
17. Activation of the classical pathway of human complement by a human monoclonal IgE, IgE(DES).
Saint-Remy JM; Magnusson CG; Masson PL
J Immunol; 1983 Mar; 130(3):1341-4. PubMed ID: 6822738
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products.
Wouters D; Voskuyl AE; Molenaar ET; Dijkmans BA; Hack CE
Arthritis Rheum; 2006 Apr; 54(4):1143-50. PubMed ID: 16572449
[TBL] [Abstract][Full Text] [Related]
19. Complement activation in Staphylococcus aureus bacteraemia.
Hallett AF; Cooper R
Clin Exp Immunol; 1980 May; 40(2):306-11. PubMed ID: 6904257
[TBL] [Abstract][Full Text] [Related]
20. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
